Harshbarger Benjamin
Insider CIK 1653133 · AEGR General Counsel and Secretary · CATB Senior VP, General Counsel · NVLN See Remarks
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics, Inc. | D To issuer deriv | 2026-01-23 | 2026-01-23 | 55,000 | — | $0 | 0 | SEC↗ |
| ATXS Astria Therapeutics, Inc. | D To issuer deriv | 2026-01-23 | 2026-01-23 | 262,500 | — | $0 | 0 | SEC↗ |
| ATXS Astria Therapeutics, Inc. | D To issuer deriv | 2026-01-23 | 2026-01-23 | 33,333 | — | $0 | 0 | SEC↗ |
| ATXS Astria Therapeutics, Inc. | A Award deriv | 2025-03-21 | 2025-03-25 | 262,500 | — | $0 | 262,500 | SEC↗ |
| ATXS Astria Therapeutics, Inc. | A Award deriv | 2024-02-08 | 2024-02-12 | 175,000 | — | $0 | 175,000 | SEC↗ |
| ATXS Astria Therapeutics, Inc. | A Award deriv | 2023-06-02 | 2023-06-06 | 90,000 | — | $0 | 90,000 | SEC↗ |
| ATXS Astria Therapeutics, Inc. | A Award deriv | 2022-03-01 | 2022-03-03 | 55,000 | — | $0 | 55,000 | SEC↗ |
| CATB CATABASIS PHARMACEUTICALS | A Award deriv | 2021-06-08 | 2021-06-10 | 200,000 | — | $0 | 200,000 | SEC↗ |
| CATB CATABASIS PHARMACEUTICALS | A Award deriv | 2021-06-02 | 2021-06-02 | 400,000 | — | $0 | 400,000 | SEC↗ |
| CATB CATABASIS PHARMACEUTICALS | A Award deriv | 2020-06-11 | 2020-06-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2019-05-09 | 2019-05-13 | 212 | $1.22 | $259 | 3,683 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2018-09-17 | 2018-11-05 | 98 | $3.94 | $386 | 3,895 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2018-05-15 | 2018-11-05 | 150 | $4.15 | $623 | 3,993 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2018-05-09 | 2018-11-05 | 322 | $4.26 | $1.4K | 4,143 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2018-04-01 | 2018-04-03 | 52 | $3.50 | $182 | 4,465 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | A Award deriv | 2018-02-12 | 2018-02-14 | 45,000 | — | $0 | 45,000 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | A Award deriv | 2017-10-06 | 2017-10-10 | 75,000 | — | $0 | 75,000 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise deriv | 2017-09-17 | 2017-09-19 | 337 | — | $0 | 336 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise | 2017-09-17 | 2017-09-19 | 337 | — | $0 | 1,782 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2017-09-17 | 2017-09-19 | 109 | $7.08 | $772 | 1,673 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise deriv | 2017-05-15 | 2017-05-17 | 717 | — | $0 | 0 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2017-05-15 | 2017-05-17 | 232 | $8.97 | $2.1K | 1,445 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise | 2017-05-15 | 2017-05-17 | 717 | — | $0 | 1,677 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise deriv | 2017-05-09 | 2017-05-11 | 349 | — | $0 | 697 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise deriv | 2017-05-09 | 2017-05-11 | 375 | — | $0 | 1,122 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise | 2017-05-09 | 2017-05-11 | 349 | — | $0 | 819 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2017-05-09 | 2017-05-11 | 113 | $9.42 | $1.1K | 706 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise | 2017-05-09 | 2017-05-11 | 375 | — | $0 | 1,081 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2017-05-09 | 2017-05-11 | 121 | $9.42 | $1.1K | 960 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise deriv | 2017-04-01 | 2017-04-04 | 178 | — | $0 | 177 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise | 2017-04-01 | 2017-04-04 | 178 | — | $0 | 527 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2017-04-01 | 2017-04-04 | 57 | $10.74 | $612 | 470 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | A Award deriv | 2016-12-22 | 2016-12-27 | 97,400 | — | $0 | 97,400 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 2,500 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 1,733 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 3,500 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 3,282 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 30,000 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 3,399 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 1,701 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 14,324 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 2,676 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 10,683 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 1,817 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 15,096 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 25,529 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 7,300 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 5,100 | — | $0 | 0 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 3,366 | — | $0 | 3,366 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 7,486 | — | $0 | 7,486 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 3,589 | — | $0 | 3,589 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 1,777 | — | $0 | 1,777 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 2,564 | — | $0 | 2,564 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 5,230 | — | $0 | 5,230 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer | 2016-11-29 | 2016-11-30 | 1,704 | — | $0 | 0 | SEC↗ |
| NVLN QLT INC/BC | A Award | 2016-11-29 | 2016-12-01 | 1,747 | — | $0 | 1,747 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | M Exercise deriv | 2016-09-17 | 2016-09-20 | 1,642 | — | $0 | 3,282 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | M Exercise | 2016-09-17 | 2016-09-20 | 1,642 | — | $0 | 2,236 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | F Tax w/h | 2016-09-17 | 2016-09-20 | 532 | $1.78 | $947 | 1,704 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2016-05-09 | 2016-05-11 | 5,100 | — | $0 | 5,100 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2016-05-09 | 2016-05-11 | 7,300 | — | $0 | 7,300 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | M Exercise deriv | 2016-04-01 | 2016-09-20 | 867 | — | $0 | 1,733 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | M Exercise | 2016-04-01 | 2016-09-20 | 867 | — | $0 | 867 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | F Tax w/h | 2016-04-01 | 2016-09-20 | 273 | $3.55 | $969 | 594 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2015-10-01 | 2015-10-05 | 30,000 | — | $0 | 30,000 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2015-09-17 | 2015-09-18 | 4,924 | — | $0 | 4,924 | SEC↗ |